Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada.
Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
BMC Psychiatry. 2024 Jun 19;24(1):460. doi: 10.1186/s12888-024-05788-y.
Psychotic disorders have long been considered neurodevelopmental disorders where excessive synaptic pruning and cortical volume loss are central to disease pathology. We conducted a systematic review of the literature to identify neuroimaging studies specifically examining synaptic density across the psychosis spectrum.
PRISMA guidelines on reporting were followed. We systematically searched MEDLINE, Embase, APA PsycINFO, Web of Science and The Cochrane Library from inception to December 8, 2023, and included all original peer-reviewed articles or completed clinical neuroimaging studies of any modality measuring synaptic density in participants with a diagnosis of psychosis spectrum disorder as well as individuals with psychosis-risk states. The NIH quality assessment tool for observational cohort and cross-sectional studies was used for the risk of bias assessment.
Five studies (k = 5) met inclusion criteria, comprising n = 128 adults (psychotic disorder; n = 61 and healthy volunteers; n = 67 and specifically measuring synaptic density via positron emission tomography (PET) imaging of the synaptic vesicle glycoprotein 2 A (SV2A). Three studies were included in our primary meta-analysis sharing the same outcome measure of SV2A binding, volume of distribution (V). Regional SV2A V was reduced in psychotic disorder participants in comparison to healthy volunteers, including the occipital lobe (Mean Difference (MD)= -2.17; 95% CI: -3.36 to -0.98; P < 0.001 ), temporal lobe (MD: -2.03; 95% CI: -3.19 to -0.88; P < 0.001 ), parietal lobe (MD:-1.61; 95% CI: -2.85 to -0.37; P = 0.01), anterior cingulate cortex (MD= -1.47; 95% CI: -2.45 to -0.49; P = 0.003), frontal cortex (MD: -1.16; 95% CI: -2.18 to -0.15; P = 0.02), amygdala (MD: -1.36; 95% CI: -2.20 to -0.52, p = 0.002), thalamus (MD:-1.46; 95% CI:-2.46 to -0.46, p = 0.004) and hippocampus (MD= -0.96; 95% CI: -1.59 to -0.33; P = 0.003).
Preliminary studies provide in vivo evidence for reduced synaptic density in psychotic disorders. However, replication of findings in larger samples is required prior to definitive conclusions being drawn.
CRD42022359018.
精神障碍长期以来被认为是神经发育障碍,其中过度的突触修剪和皮质体积损失是疾病病理的核心。我们进行了系统的文献综述,以确定专门研究整个精神病谱中突触密度的神经影像学研究。
我们遵循 PRISMA 关于报告的指南。我们系统地搜索了 MEDLINE、Embase、APA PsycINFO、Web of Science 和 The Cochrane Library,从成立到 2023 年 12 月 8 日,纳入了所有原始同行评议的文章或任何模态的完成的临床神经影像学研究,这些研究测量了患有精神病谱障碍的参与者以及有精神病风险状态的个体的突触密度。我们使用 NIH 对观察性队列和横断面研究的质量评估工具来评估偏倚风险。
五项研究(k=5)符合纳入标准,包括 n=128 名成年人(精神病;n=61 名和健康志愿者;n=67 名,专门通过正电子发射断层扫描(PET)测量突触小泡糖蛋白 2A(SV2A)的突触密度。有三项研究纳入了我们的主要荟萃分析,它们共享 SV2A 结合的相同结果测量,即分布容积(V)。与健康志愿者相比,精神病患者的 SV2A V 减少,包括枕叶(平均差异(MD)=-2.17;95%置信区间:-3.36 至 -0.98;P<0.001)、颞叶(MD:-2.03;95%置信区间:-3.19 至 -0.88;P<0.001)、顶叶(MD:-1.61;95%置信区间:-2.85 至 -0.37;P=0.01)、前扣带皮层(MD=-1.47;95%置信区间:-2.45 至 -0.49;P=0.003)、额叶(MD:-1.16;95%置信区间:-2.18 至 -0.15;P=0.02)、杏仁核(MD:-1.36;95%置信区间:-2.20 至 -0.52,P=0.002)、丘脑(MD:-1.46;95%置信区间:-2.46 至 -0.46,P=0.004)和海马(MD=-0.96;95%置信区间:-1.59 至 -0.33;P=0.003)。
初步研究提供了精神障碍中突触密度降低的体内证据。然而,在得出明确结论之前,需要在更大的样本中复制这些发现。
CRD42022359018.